Abattis Bioceuticals Corp. (ATTBF)
Abattis Bioceuticals Corp. (ATTBF) is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. It develops and licenses medicines, natural health products, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets.
Its outstanding shares are standing around 76,802,135, while the company can authorized unlimited shares. It has also been issuing its shares to employees and directors against their remuneration. Its shares are currently trading around $0.02 per share with a 52-week range of $0.01 – $0.09. The company has market capitalization of $1.90M and average volume of 157609 shares.
Based on Yahoo finance, it had generated approximately $23k in revenues in the trailing twelve months. In the near-term, it will be important for Abattis to show how it can produce incomes rapidly.
I like that Abattis is an innovation consolidator. There is a genuine business opportunity by that the company can acquire other companies to expand its presence. One of the greatest challenges for marijuana business is that specialists are the small producers. Therefore, expanding business through acquisitions is a good strategy.
Abattis Bioceuticals is in position to wind up a pioneer in the developing, testing, and circulation of therapeutic and grown-up use cannabis in North America.
Abattis recently completed a US$25 million equity line agreement with Dutchess Opportunity Fund. It has agreed to file a registration statement with the U.S. Securities & Exchange Commission covering the Abattis shares that may be issued to Dutchess under this financing.
Overall, it appears that Abattis has strong liquidity position and the company is in a position to support its expansion strategies. Enhancing liquidity situation through equity offerings is a good strategy for any company in its early stages.